Recently, a phase 3 trial reported that resmetirom, a thyroid hormone receptor beta (THR-β)-selective agonist, improved nonalcoholic steatohepatitis (NASH) or fibrosis resolution in NASH patients with liver fibrosis 6,7. This evidence concerns the gene THRB and metabolic dysfunction-associated steatohepatitis.